Esperion Therapeutics (ESPR) Other Gross PP&E Adjustments (2018 - 2025)
Esperion Therapeutics (ESPR) has disclosed Other Gross PP&E Adjustments for 8 consecutive years, with -$2.6 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Other Gross PP&E Adjustments rose 91.05% year-over-year to -$2.6 million, compared with a TTM value of -$2.6 million through Dec 2025, up 91.05%, and an annual FY2025 reading of -$2.6 million, up 91.05% over the prior year.
- Other Gross PP&E Adjustments was -$2.6 million for Q4 2025 at Esperion Therapeutics, up from -$3.3 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$730000.0 in Q3 2022 and bottomed at -$29.2 million in Q4 2024.
- Average Other Gross PP&E Adjustments over 5 years is -$8.3 million, with a median of -$4.2 million recorded in 2021.
- The sharpest move saw Other Gross PP&E Adjustments plummeted 563.26% in 2024, then surged 91.05% in 2025.
- Year by year, Other Gross PP&E Adjustments stood at -$21.9 million in 2021, then fell by 12.07% to -$24.6 million in 2022, then dropped by 14.3% to -$28.1 million in 2023, then dropped by 4.17% to -$29.2 million in 2024, then soared by 91.05% to -$2.6 million in 2025.
- Business Quant data shows Other Gross PP&E Adjustments for ESPR at -$2.6 million in Q4 2025, -$3.3 million in Q3 2025, and -$4.2 million in Q2 2025.